Voluntary Suspension of Marketing Tysabri Due to Death and Progressive Multifocal Leukoencephalopathy (PML)

Kahn Gauthier Swick is investigating possible legal actions against Biogen Idec and Elan because of two adverse events reported with the use of Tysabri (Natalizumab). Tysabri is used to treat MS (multiple sclerosis). The FDA received reports of one confirmed death and one possible case of progressive multifocal leukoencephalopathy (PML) in patients taking Tysabri.

Biogen Idec is suspending dosing of Tysabri in clinical trials and is notifying patients and investigators of the possible association between Tysabri and PML.

PML, or Progressive Multifocal Leukoencephalopathy, is a rare, serious, progressive neurologic disease, usually occurring in immunosuppressed patients, often resulting in irreversible neurologic deterioration and death. There is no known effective treatment for PML, although reversing immune system suppression may slow or arrest progression of the disease. No cases of PML were observed during the clinical trials performed prior to approval of Tysabri.

If you or a loved one have PML, or if a loved one has died, due to taking Tysabri and would like to speak to a lawyer, please call toll free 1-866-467-1400 now, or make a claim on this page.